Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on June 17, 2020, covering events that occurred on June 11, 2020. The company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market under the symbol "TRVI". The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes
- Board Departure: Annie Mitsak, Ph.D., resigned from her position as a member of the Board of Directors on June 11, 2020. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Elections: At the 2020 annual meeting of stockholders, James Cassella, Ph.D., and Michael Heffernan were elected as Class I directors for terms expiring at the 2023 annual meeting.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document strictly reports on the outcomes of the annual stockholder meeting and the resignation of a director.
Investor Verification Checklist
- Verify the impact of Dr. Mitsak's resignation on the Board's composition and expertise.
- Review the voting results for the newly elected directors (James Cassella and Michael Heffernan) to assess stockholder support.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2020 fiscal year.
- Check subsequent filings for any financial updates or strategic changes following the annual meeting.